Biowaiver monographs for immediate release solid oral dosage forms: prednisone.

Area of Science:

• Pharmaceutical Sciences
• Drug Regulatory Affairs

Background:

• The Biopharmaceutics Classification System (BCS) guides decisions on waiving in vivo bioequivalence (BE) testing for drug product approval.
• Prednisone's solubility and permeability data place it on the borderline of BCS Class I criteria, complicating definitive classification.
• Regulatory approval of immediate-release (IR) solid oral dosage forms often relies on BE studies, but waivers can streamline the process.

Purpose of the Study:

• To review available literature data concerning prednisone's properties relevant to bioequivalence (BE) waiver decisions.
• To assess the feasibility and patient safety implications of granting a biowaiver for IR solid oral prednisone dosage forms.

Main Methods:

• Comprehensive literature review of prednisone's solubility, permeability, pharmacokinetic properties, and therapeutic index.
• Consideration of potential interactions between prednisone and common excipients used in IR solid oral dosage forms.
• Evaluation of prednisone's classification within the Biopharmaceutics Classification System (BCS) based on existing data.

Main Results:

• Prednisone's borderline solubility and permeability prevent definitive classification under current BCS criteria.
• Analysis of therapeutic indications, index, pharmacokinetics, and excipient interactions did not reveal significant risks.
• Evidence suggests that a biowaiver for specific IR prednisone formulations is unlikely to increase patient risk.

Conclusions:

• A definitive BCS classification for prednisone remains challenging due to borderline solubility and permeability data.
• Based on current evidence, granting a biowaiver for IR solid oral dosage forms containing specific excipients is likely safe.
• Further data may be needed for a conclusive regulatory decision on biowaivers for prednisone products.